Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TNGX Tango Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TNGX
Price (delayed)
$4.65
Market cap
$504.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$482.12M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
Highlights
The debt has contracted by 3.4% YoY
The gross profit rose by 10% year-on-year but it has declined by 2.6% since the previous quarter
The revenue rose by 10% YoY but it fell by 2.6% QoQ
The equity has decreased by 37% YoY and by 16% QoQ
Tango Therapeutics's quick ratio has decreased by 25% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of TNGX
Market
Valuations
Earnings
Shares outstanding
108.39M
Market cap
$504.03M
Enterprise value
$482.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.01
Price to sales (P/S)
12.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.76
Revenue
$40.99M
Gross profit
$40.99M
Operating income
-$145.87M
Net income
-$132.26M
EBIT
-$132.06M
EBITDA
-$125.73M
Free cash flow
-$135.95M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
-$1.23
Book value per share
$1.54
Revenue per share
$0.37
TBVPS
$2.49
Total assets
$274.31M
Total liabilities
$107.55M
Debt
$36.95M
Equity
$166.76M
Working capital
$189.01M
Debt to equity
0.22
Current ratio
6.26
Quick ratio
6.05
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-306.7%
Gross margin
100%
Net margin
-322.7%
Operating margin
-355.9%
Return on assets
-39.9%
Return on equity
-62.8%
Return on invested capital
-48.7%
Return on capital employed
-55.4%
Return on sales
-322.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNGX stock price
How has the Tango Therapeutics stock price performed over time
Intraday
-7.92%
1 week
9.15%
1 month
232.14%
1 year
-44.58%
YTD
50.49%
QTD
239.42%
Financial performance
How have Tango Therapeutics's revenue and profit performed over time
Revenue
$40.99M
Gross profit
$40.99M
Operating income
-$145.87M
Net income
-$132.26M
Gross margin
100%
Net margin
-322.7%
The company's net income fell by 18% YoY
Tango Therapeutics's operating income has decreased by 16% YoY
The gross profit rose by 10% year-on-year but it has declined by 2.6% since the previous quarter
The revenue rose by 10% YoY but it fell by 2.6% QoQ
Price vs fundamentals
How does TNGX's price correlate with its fundamentals
Growth
What is Tango Therapeutics's growth rate over time
Valuation
What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
3.01
P/S
12.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.76
Tango Therapeutics's EPS has decreased by 9% YoY
The equity has decreased by 37% YoY and by 16% QoQ
The stock's P/B is 31% more than its last 4 quarters average of 2.5 but 27% less than its 5-year quarterly average of 4.5
TNGX's price to sales (P/S) is 37% lower than its 5-year quarterly average of 21.6 but 3% higher than its last 4 quarters average of 13.2
The revenue rose by 10% YoY but it fell by 2.6% QoQ
Efficiency
How efficient is Tango Therapeutics business performance
The ROA is down by 45% year-on-year and by 11% since the previous quarter
TNGX's ROIC is down by 45% YoY and by 13% from the previous quarter
The ROE is down by 42% year-on-year and by 13% since the previous quarter
Tango Therapeutics's return on sales has decreased by 8% YoY and by 4.2% QoQ
Dividends
What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNGX.
Financial health
How did Tango Therapeutics financials performed over time
The total assets is 155% more than the total liabilities
The total assets has contracted by 32% YoY and by 13% from the previous quarter
Tango Therapeutics's quick ratio has decreased by 25% YoY and by 11% from the previous quarter
The debt is 78% less than the equity
The debt to equity has surged by 57% year-on-year and by 22% since the previous quarter
The equity has decreased by 37% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.